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Rabbit antithymocyte globulin (ATG) is administered during transplant conditioning to decrease the risk of
both acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD). Here we
evaluated the relationship between the serum concentration of ATG (capable of binding to lymphocytes)
immediately before graft infusion (day 0) or on day þ7 or þ28 post-transplantation and the development of
aGVHD or cGVHD. We studied 180 patients whose conditioning included 4.5 mg/kg antithymocyte globulin
(ATG; Thymoglobulin). For aGVHD, we found no association with ATG levels on day 0. Nevertheless, high
day þ7 and þ28 ATG levels were associated with a low likelihood of aGVHD. For cGVHD, high ATG levels at all
3 time points (days 0, þ7, and þ28) were associated with a low likelihood of cGVHD. In conclusion, high-dose
ATG administration at the time of graft infusion appears to inhibit the development of cGVHD, but not
aGVHD; however, higher ATG levels on days þ7 and þ28 are associated with lower rates of both aGVHD and
cGVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION differences in the number of recipient cells that can adsorb or
The addition of rabbit antithymocyte globulin (ATG) to
pretransplantation conditioning has been shown to decrease
the incidence of acute graft-versus-host disease (aGVHD)
and chronic graft-versus-host disease (cGVHD) in recipients
of both unrelated and related donor grafts [1-11]. Two brands
of rabbit ATG are available: Thymoglobulin (Genzyme/Sanoﬁ,
Cambridge, MA), produced from sera of rabbits immunized
with human thymocytes, and ATG-F (Fresenius, Bad Hom-
burg, Germany), produced from sera of rabbits immunized
with Jurkat T cells. In both cases, ATG is produced by puriﬁ-
cation of IgG from the immune sera.
ATG is polyclonal and contains antibodies against anti-
gens expressed on lymphocytes, other leukocytes, and non-
leukocytes [12-15]. It is generally believed that the fraction of
antibodies within ATG that can bind to lymphocytes is the
functional (ie, anti-GVHD) fraction. Consistent with this idea,
we have reported that high serum levels of this fraction on
days þ7 and þ28 were associated with a low likelihood of
both aGVHD and cGVHD [16]. We hypothesized that day
0 levels may be even more strongly associated with GVHD
than day þ7/þ28 levels, because the day 0 levels should not
be inﬂuenced by the variability in ATG elimination between
day 0 and dayþ7/þ28. The variability in elimination could be
related to, for example, differences in graft content of cells
that can adsorb ATG (on target antigens or Fc receptors) oredgments on page 1161.
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The primary objective of the present study was to eval-
uate the associations between the day 0, þ7, and þ28 ATG
levels and aGVHD/cGVHD. The secondary objective was to
evaluate associations between the day 0, þ7, and þ28 levels
and relapse, cytomegalovirus (CMV) reactivation, post-
transplantation lymphoproliferative disorder (PTLD), and
death.
PATIENTS AND METHODS
Patients and Transplantation
We studied 185 consecutive recipients of allogeneic ﬁlgrastim-mobilized
peripheral blood stem cells (PBSCs) for a hematologic malignancy who con-
sented to participate in the study. All patients received ATG (Thymoglobulin)
as part of pretransplantation conditioning. All transplantations were per-
formed between December 2008 and December 2012. Patients who failed to
engraft (n ¼ 3), relapsed (n ¼ 0), or died (n ¼ 2) before day þ30 were
excluded; their ATG levels on days 0,þ7 andþ28were notmarkedly different
compared with the 180 patients included in the study, data for whom we
report here. For 177 of these 180 patients, conditioning consisted of ﬂudar-
abine 250mg/m2, busulfanw12.8mg/kg (pharmacokinetically adjusted), and
ATG 0.5 mg/kg on day -2, 2.0 mg/kg on day -1, and 2.0 mg/kg on day 0 (total,
4.5 mg/kg) [7]. The last dose of ATG (day 0 dose) was given before graft
infusion. Total body irradiation (TBI; 4 cGy) was also administered to 133
patients [17]. Table 1 shows patient and donor characteristics.
Post-transplantation GVHD prophylaxis consisted of cyclosporine from
day -1 up to 3 months post-transplantation, at a starting dose of 2.5 mg/kg
every 12 hours and later targeting trough serum levels of 200 to 400 g/L and
methotrexate on days þ1, þ3, þ6, and þ11 (ﬁrst dose, 15 mg/m2 IV; next 3
doses, 10 mg/m2 IV; the last dose was omitted in rare patients with airway-
jeopardizing mucositis) [7]. No antifungal prophylaxis was given routinely
until 2010; thereafter, ﬂuconazole was given on days 0 to þ28. Routine
antibacterial prophylaxis was not provided, except for trimethoprim-
sulfamethoxazole for pneumocystis prophylaxis given up to 6 months
post-transplantation or longer in cases of cGVHD requiring systemic ther-
apy. Viral prophylaxis consisted of acyclovir or valacyclovir for up to 2 yearsTransplantation.
Table 1
Patient and Donor Characteristics
Characteristic Value
Total patients, n 180
Patients with day 0 serum samples, n 152
Patients with day 7 serum samples, n 164
Patients with day 28 serum samples, n 160
Patient age at transplantation, yr, median (range) 50 (18-66)
Donor age at transplantation, yr, median (range) 36 (13-68)
Patient sex, M/F, n 104/76
Donor sex, M/F, n 116/64
Diagnosis, n
Acute lymphoblastic leukemia 35
Acute myelogenous leukemia 68
Chronic lymphocytic leukemia 15
Chronic myelogenous leukemia 7
Myelodysplastic syndrome 21
Non-Hodgkin lymphoma 13
Myeloﬁbrosis 10
Other hematologic malignancies 9
Disease risk stage, n*
Good 94
Poor 86
Donor type, n
HLA-matched sibling 67
Others 113
HLA match (-A, -B, -C, -DRB1, and -DQB1), n
10/10 allele-matched 153
8-9/10 allele-matched 27
Conditioning regimen, n
Flu þ Bu þ ATG þ TBI 131
Flu þ Bu þ ATG 46
Flu þ Cy þ ATG þ TBI 2
Cy þ Bu þ ATG 1
Acute GVHDy grade, n
Grade 0 81
Grade I 51
Grade II 26
Grade III 15
Grade III-IV 1
Grade IV 5
Median day of onset of grade II-IV aGVHD (range) 56 (15-99)
Chronic GVHD,z n
None 84
NNST 20
NST 48
Not applicablex 28
Median onset day of chronic GVHD NST (range) 126 (89-446)
Number of patients with CMV reactivation above
threshold for preemptive therapy
45
Median day of onset of CMV reactivation (range) 43.5 (20-175)
Number of patients with PTLD 15
Median day of onset of PTLD (range) 55.5 (33-408)
Number of patients with relapse 33
Median day of onset of relapse (range) 182 (39-946)
Median day of follow-up for death (range)k 448 (31-1448)
Median day of follow-up for death in patients who
did not die (range)
566 (68-1448)
Median day of follow-up for relapse and nonrelapse
death (range){
422 (31-1448)
Median day of follow-up for relapse and nonrelapse
death in patients who did not relapse or die
(range)
547 (59-1448)
Median day of follow-up for GVHD, CMV
reactivation and PTLD (range)**
387 (31-1448)
(Continued)
Table 1
(continued)
Characteristic Value
Median day of follow-up for GVHD, CMV
reactivation and PTLD in patients who did not
develop graft failure, relapse, secondary
malignancy, or death
564 (59-1448)
Flu indicates ﬂudarabine; Bu, busulfan; TBI, total body irradiation; Cy,
cyclophosphamide.
* Good risk disease/stage includes primary acute leukemia in ﬁrst
remission, chronic myelogenous leukemia in ﬁrst chronic phase, and mye-
lodysplasia with <5% marrow blasts. All other diseases/disease stages were
considered poor risk.
y aGVHD occurred in 66 of 113 (58.4%) unrelated transplant recipients
and in 34 of 65 (52.3%) matched sibling transplant recipients (P ¼ .4297, chi
square test).
z cGVHD occurred in 40 of 100 (40%) unrelated transplant recipients and
in 28 of 56 (50%)matched sibling transplant recipients (P¼ .2269, chi square
test).
x Patients who developed second malignancy, relapse, or death or were
lost to follow-up before day 100.
k Patients were followed until death or until the last day known to be
alive.
{ Patients were followed until they developed relapse or death or were
lost to follow-up.
** Patients were followed until they developed graft failure, second
malignancy (including PTLD), relapse, or death, or until they were lost to
follow-up (deﬁned as the last day on which medically meaningful infor-
mation was available).
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and a preemptive CMV strategy [18].Measurement of ATG Levels
Blood was drawn from patients on day 0 (within 15 minutes before graft
infusion), day þ7 (range, day þ6 to day þ8), and day 28 (range, day þ24 to
day þ36) post-transplantation. Serum was stored in tightly sealed vials at
minus 80C until ATG level determination. We measured ATG levels(capable of binding to lymphocytes) using the ﬂow cytometryebased assay
developed by Kakhniashvili et al. [19] with minor modiﬁcations [16]. In
brief, standards of known ATG concentrations, ranging from 20 to 0.0098
mg/L were prepared by serial 2-fold dilution. Peripheral blood mononuclear
cells from a healthy volunteer were incubated with patient serum or an
ATG standard. The cells (coated with ATG) were then labeled with
phycoerythrin-conjugated goat anti-rabbit IgG. After ﬂow cytometry data
acquisition, lymphocytes were gated by forward and side scatter charac-
teristics. Phycoerythrin ﬂuorescence was measured for each standard and
for each patient serum sample included in the run. Plotting ATG levels of
standards versus the median channel of phycoerythrin ﬂuorescence
generated a standard curve, from which patient ATG levels were then
extrapolated.
Deﬁnitions of Outcomes
aGVHD and cGVHD were categorized according to National Institutes of
Health (NIH) criteria [20]. A minority of patients with insufﬁcient infor-
mation in their charts for unequivocal categorization of posteday þ100
GVHD as cGVHD versus late aGVHDwere classiﬁed as having cGVHD. aGVHD
was graded in accordance with the 1994 consensus conference [21]. Chronic
GVHDwas graded as none, not needing systemic therapy (NNST), or needing
systemic therapy (NST). “Any cGVHD” refers to cGVHD NNSTor NST. Relapse,
death, and nonrelapse death were deﬁned using standard criteria. CMV
reactivationwas deﬁned as CMV DNAemia above our institutional threshold
for preemptive antiviral therapy (25,000 IU/mL plasma) or CMV disease.
PTLD was deﬁned as an illness with signs or imaging results consistent with
PTLD (eg, fever not due to other causes, lymphadenopathy, splenomegaly,
mass) with Epstein-Barr virus (EBV) DNAemia >400 copies/mg of leukocyte
DNA or >40,000 copies/mL whole blood or histological evidence of PTLD,
including in situ hybridization for EBV-encoded RNA.
Statistics
ATG levels in patients with versus patients without grade II-IV aGVHD,
grade III-IV aGVHD, any cGVHD, cGVHD NST, relapse, death, nonrelapse
death, CMV reactivation, and PTLD were compared using the Mann-
Whitney-Wilcoxon (MWW) test. For outcomes for which ATG levels
appeared to differ signiﬁcantly between patients with and thosewithout the
outcome (P  .05, MWW test), we proceeded to multivariate analysis. Using
log-binomial regression models, we determined whether patients with ATG
levels above the cutoff had a higher/lower likelihood of the outcome
compared with patients with ATG levels below the cutoff (multivariate
analysis adjusting for confounding factors known to be associated with the
outcome). The cutoff ATG levels were determined using the receiver oper-
ating characteristic (ROC) curve as the cutoff associated with the highest
sum of sensitivity and speciﬁcity. To avoid having too small patient groups
Figure 1. Association (or lack of association) between ATG level and GVHD in univariate analysis. Horizontal bars indicate median values. P values shown are from the
MWW rank-sum test. NS, not signiﬁcant; NST, needing systemic therapy.
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90th percentiles were considered. Confounding factors (covariates)
considered in the multivariate analyses for aGVHD and cGVHD were recip-
ient age (above versus below 45 years), donor age (above versus below 45
years), donor type (HLA-matched sibling versus other), and donor/recipient
sex match (M/M versus other). For CMV reactivation, we considered donor/
recipient CMV serostatus (/, /þ, þ/þ, and þ/), presence of signiﬁcant
GVHD (either grade II-IV aGVHD or cGVHD NST) before CMV reactivation
(yes versus no), and donor type (HLA-matched sibling versus other). For
PTLD, we considered donor/recipient EBV serostatus (þ/þ versus other,
including unknown), presence of signiﬁcant GVHD (either grade II-IV
aGVHD or cGVHD NST) before PTLD onset (yes versus no), donor type
(HLA-matched sibling versus other), and recipient age (above versus below
45 years) [22,23].
Batch of ATG was not included as a covariate in any of the multivariate
analyses, because batch-to-batch variability in ATG potency has been shown
to be minimal [24,25]. In cases of nonconvergence of log-binomial regres-
sion, Poisson regression with Huber-White sandwich robust variance [26]
was used to approximate the log-binomial model.
Because the ATG levels were skewed toward lower levels, we also ran all
multivariate analyses using log-transformed ATG levels. The results were
virtually identical to those obtained using raw ATG levels; thus, only the
results obtained with the raw ATG levels are shown.
MWW test analyses were performed using Prism software (GraphPad
Software, La Jolla, CA). ROC curve analysis and Spearman’s rank correlation
test were performed using MedCalc software (MedCalc, Mariakerke,
Belgium). All multivariate analyses were performed using Stata software
(StataCorp, College Station, TX).RESULTS
GVHD
ATG levels on day 0
Univariate analysis revealed no signiﬁcant association
between ATG levels on day 0 and the development of aGVHD
grade II-IV or aGVHD grade III-IV (Figure 1 and Table 2).
However, patients who developed any cGVHD had lower ATG
levels compared with those who did not develop cGVHD (P<
.001), and patients who developed cGVHD NST had lower
ATG levels comparedwith those who did not develop cGVHD
or had cGVHD NNST (P ¼ .003). The association between day
0 ATG level and cGVHD was also signiﬁcant in multivariate
analyses (Table 2). Patients with an ATG level >8.12 mg/L on
day 0 had a 0.5-fold risk of developing any cGVHD (P < .001)
compared with those with an ATG level <8.12 mg/L. Simi-
larly, patients with an ATG level >7.83 mg/L on day 0 had a
0.4-fold risk of developing cGVHD NST (P < .001) compared
with those with an ATG level <7.83 mg/L.
ATG level on day þ7
As shown in Figure 1 and Table 2, in both univariate and
multivariate analyses, there was a signiﬁcant association
between low day þ7 ATG level and either aGVHD or cGVHD.
Table 2
Association (or Lack of Association) between ATG Level and GVHD
Acute GVHD Grade II-IV Acute GVHDGrade III-IV Any Chronic GVHD,
NNST or NST
Chronic GVHD, NST
Yes No Yes No Yes No Yes No
ATG levels on day
Median ATG levels 9.788 9.049 11.780 9.413 6.977 10.590 6.589 10.080
P value* .770 .778 <.001 .003
Cutoff ATG level >8.12 >7.83
Adjusted relative risk (95% CI) 0.5 (0.3-0.7) 0.4 (0.2-0.6)
Adjusted P valuey <.001 <.001
ATG levels on day 7
Median ATG level 1.255 1.915 1.078 1.907 1.126 2.051 0.846 2.067
P value* .002 .005 <.001 <.001
Cutoff ATG level >1.29 >1.41 >1.26 >1.26
Adjusted relative risk (95% CI) 0.3 (0.2-0.6) 0.3 (0.1-0.8) 0.4 (0.2-0.5) 0.2 (0.1-0.3)
Adjusted P valuey <.001 .012 <.001 <.001
ATG levels on day 28
Median ATG level 0.084 0.153 0.049 0.152 0.086 0.187 0.081 0.186
P value* <.001 <.001 .002 <.001
Cutoff ATG level >0.14 > 0.08 >0.14 >0.14
Adjusted relative risk (95% CI) 0.4 (0.2-0.8) 0.2 (0.1-0.6) 0.6 (0.4-0.9) 0.3 (0.2-0.6)
Adjusted P valuey .005 .006 .008 .001
* Mann-Whitney-Wilcoxon test (univariate analysis).
y Log-binomial regression (multivariate analysis).
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Similar to day þ7, in both univariate and multivariate
analyses, there was a signiﬁcant association between low
dayþ28 ATG level and both aGVHD and cGVHD (Figure 1 and
Table 2).
Outcomes Other Than GVHD
No signiﬁcant associations were found between ATG level
on day 0, day þ7, or day þ28 and relapse, death, or non-
relapse death (Table 3). For CMV reactivation, there was no
signiﬁcant association with ATG level on day 0 or day þ7.
There appeared to be an association between low day 28 ATG
level and CMV reactivation in univariate analysis, but not in
multivariate analysis (Table 3). For PTLD, there was no sig-
niﬁcant association with ATG level on day 0; however,
consistent with our previous observation [16], signiﬁcantTable 3
Association (or Lack of Association) between ATG Levels and Clinical Outcomes Ot
Variable Relapse Death
Yes No Yes No
ATG level on day 0
Median ATG level 9.003 9.401 8.291 9.359
P valuey .596 .471
Cutoff ATG level
Adjusted relative risk (95% CI)
Adjusted P valuez
ATG level on day 7
Median ATG level 2.031 1.789 2.030 1.852
P valuey .129 .660
Cutoff ATG level
Adjusted relative risk (95% CI)
Adjusted P valuez
ATG level on day 28
Median ATG level 0.152 0.127 0.112 0.140
P valuey .300 .647
Cutoff ATG level
Adjusted relative risk (95% CI)
Adjusted P valuez
* CMV reactivation above threshold for preemptive therapy.
y MWW test (univariate analysis).
z Log-binomial regression (multivariate analysis).associations between high day þ7 and day þ28 ATG level
and PTLD were noted in both univariate and multivariate
analyses (Table 3).
Decrease in ATG Level and GVHD
Given the association between day þ7 and day þ28, but
not day 0 ATG level and aGVHD, we hypothesized that
aGVHD may be associated with the decrease in ATG level
from day 0 to day þ7 or þ28 (which depends on the rate of
ATG elimination from serum), rather than with the level on
day 0. Consistent with this hypothesis, a high relative
decrease in ATG level from day 0 to day þ7 was associated
with subsequent aGVHD in both univariate and multivariate
analyses (Table 4). Analogously, a high relative decrease in
ATG level from day 0 to day þ28 also was associated with
aGVHD (Table 4). For cGVHD, we found no signiﬁcanther Than GVHD
Nonrelapse
Death
CMV Reactivation* PTLD
Yes No Yes No Yes No
9.187 9.206 10.430 8.815 11.480 8.909
.679 .509 .222
1.734 1.869 1.734 1.875 3.116 1.746
.500 .406 .012
>1.87
5.1 (1.5-17.5)
. 010
0.084 0.138 0.090 0.152 0.331 0.120
.219 .024 <. 001
>0.10 >0.15
0.7 (0.4-1.2) 9.7 (2.3-42.9)
.192 .002
Table 4
Association (or Lack of Association) between Relative Decrease in ATG Level
and GVHD
Acute GVHD* Chronic
GVHD*
Yes No Yes No
Relative decrease in ATG level from day 0 to day 7y
Median ATG drop, % 82.19 78.93 82.59 78.04
P valuez .005 .129
Cutoff ATG drop, % >87.85
Adjusted relative risk (95% CI) 2.7 (1.5-4.9)
Adjusted P valuex .001
Relative decrease in ATG level from day 0 to day 28{
Median ATG drop, % 99.10 97.89 98.93 98.27
P valuez .011 .245
Cutoff ATG drop, % >98.56
Adjusted relative risk (95% CI) 2.6 (1.4-4.9)
Adjusted P valuex .002
* Acute GVHD indicates acute GVHD grade II-IV; chronic GVHD indicates
any chronic GVHD.
y Percentage decrease in ATG level from day 0 to day 7.
z Mann-Whitney-Wilcoxon test (univariate analysis).
x Log-binomial regression (multivariate analysis).
{ Relative decrease indicates the percentage decrease in ATG level from
day 0 to day 28.
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0 to day þ7 or from day 0 to day þ28 (Table 4).
We also estimated the clearance and half-life of ATG in
patients in whom sera were available at all 3 time points
(days 0,þ7, andþ28) (n¼ 130), and determined whether the
clearance was associated with GVHD. ATG clearance was
estimated using the formula Cl ¼ dose/AUC, where dose is
the administered dose of ATG and AUC is the area under the
serum concentration versus time curve [27]. Themedian ATG
clearance was 0.023 L/kg/day (range, 0.005 to 0.26 L/kg/day),
and the median half-life was 5 days (range, 2.2 to 16.2 days).
There was a signiﬁcant association between ATG clearance
and aGVHD grade II-IV in both univariate analysis (median
clearance in patients with aGVHD grade II-IV, 0.028 L/kg/day,
in patients without aGVHD grade II-IV, 0.021 L/kg/day; P ¼
.028, MWW test; Table 5) and multivariate analysis (patients
with clearance >0.011 L/kg/day had a 9.4-fold increased
likelihood of developing aGVHD grade II-IV compared with
those with clearance <0.011 L/kg/day; P ¼ .025). Similarly,
patients who developed cGVHD had signiﬁcantly higher
clearance compared with those without cGVHD in both
univariate and multivariate analyses (Table 5).Decrease in ATG Level and Immune Cell Subset Counts
We also evaluated whether the decrease in ATG level
(capable of binding to lymphocytes) from day 0 to day þ28
was related to lymphocyte subset counts. In 32 patients, weTable 5
Association (or Lack of Association) between ATG Clearance and GVHD
Variable Acute GVHD
Grade II-IV
Acute GVHD
Grade III-IV
Yes No Yes
Median ATG clearance, L/kg/day 0.028 0.021 0.030
P value* .030 .058
Cutoff ATG level >0.011
Adjusted relative risk (95% CI) 9.4 (1.3-65.7)
Adjusted P valuey .025
* Mann-Whitney-Wilcoxon test (univariate analysis).
y Log-binomial regression (multivariate analysis).measured blood counts of T, B, and natural killer cells on
day þ28; the counts were too low to measure on days
0 and þ7 [28]. There was a signiﬁcant correlation between
the relative decrease in ATG level from day 0 to day þ28 and
the day þ28 T cell count (Table 6).
We then evaluated possible associations between total
WBC or lymphocyte count in transplant recipients and the
decrease in ATG level. Day 0WBC count was available for 123
patients. In 87 of these 123 patients, the WBC was <0.5/nL,
and thus, in accordance with our hematology laboratory’s
policy, a differential blood count was not performed. In the
remaining 35 patients, the WBCs were composed only of
neutrophils and monocytes, with no lymphocytes, eosino-
phils, or basophils detected. There was no signiﬁcant asso-
ciation between the relative decrease in ATG level from day
0 to day þ7 (n ¼ 35) and the day 0 WBC count (Spearman’s
correlation coefﬁcient, r¼ 0.215; P¼ .22). Dayþ7WBC count
was <0.5/nL in all patients; given the inaccuracy of mea-
surement of WBC <0.5/nL, we did not evaluate for a possible
association between day þ7WBC count and decrease in ATG
level. On day þ28, WBC count was consistently >0.5/nL.
There was no signiﬁcant association between the relative
decrease in ATG level from day 0 to day þ28 (n ¼ 107) and
WBC count on day 28 (r ¼ 0.035; P ¼ .72). Similarly, no sig-
niﬁcant association was found between the relative decrease
in ATG level from day 0 to dayþ28 (n¼ 107) and lymphocyte
count on day þ28 (r ¼ 0.133; P ¼ .173).
We next evaluated for a possible association between
graft WBC or mononuclear cell (MNC) count and decreased
ATG level in 110 patients. There was no signiﬁcant associa-
tion between the relative decrease in ATG level from day 0 to
day þ7 and total WBCs in grafts (r ¼ 0.048; P ¼ .620). Simi-
larly, there also was no signiﬁcant association between the
relative decrease in ATG level from day 0 to dayþ7 and MNC
count in grafts (r ¼ 0.147; P ¼ .151).
We then evaluated possible association between ATG
clearance and recovery of WBCs or lymphocytes by day þ28
(n ¼ 101). We found no signiﬁcant association between
the clearance of ATG and total WBC count on day þ28
(r ¼ 0.108; P ¼ .280). Similarly, there was no signiﬁcant
association between ATG clearance and total lymphocyte
count on day þ28 (r ¼ 0.043; P ¼ .670).DISCUSSION
GVHD is a major obstacle to safe allogeneic trans-
plantation. In the present study, we found that low serum
levels of ATG on day 0 were associated with a high likelihood
of cGVHD, but not aGVHD (either grade II-IV or grade III-IV).
In contrast, low day þ7 and þ28 levels were associated
with both aGVHD and cGVHD, consistent with our previous
study [16]. In disagreement with our present results,Any Chronic GVHD,
NNST or NST
Chronic GVHD, NST
No Yes No Yes No
0.022 0.037 0.019 0.047 0.019
< .001 < .001
>0.029 >0.029
2.9 (2.0-4.4) 5.5 (2.9-11)
< .001 < .001
Table 6
Correlation between Relative Decrease in ATG Level and Immune Cell Subset
Counts
Immune Cell
Subset
R* P Value
Correlation between relative
decrease in ATG level from
day 0 to day 28 and cell
count on day 28y
T cell 0.696 <.001
B cell 0.134 NS
NK cell 0.197 NS
NS indicates not signiﬁcant.
* Spearman’s rank correlation coefﬁcient.
y Relative decrease refers to the percentage decrease in ATG level from
day 0 to day 28.
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high ATG levels on day 0 and low likelihood of aGVHD.
However, there are some major differences between the 2
studies that might have inﬂuenced the results. Remberger
and Sundberg included both bone marrow and PBSC re-
cipients, whereas we included only PBSC recipients. The last
dose of ATG was given on the day before graft infusion (day
-1) to Remberger and Sundberg’s patients, compared with
the day of graft infusion (day 0) in our patients. Furthermore,
Remberger and Sundberg used historical criteria for catego-
rizing GVHD as acute (before day þ100) or chronic (after
day þ100), whereas we used NIH criteria [20]. Thus, patients
who developed NIH-deﬁned cGVHD before day þ100 were
likely categorized in by Remberger and Sundberg as aGVHD,
which theoretically could contribute to their ﬁnding of the
association between day 0 ATG level and aGVHD (deﬁned as
preeday þ100 GVHD).
An important consideration is that Remberger and
Sundberg measured total ATG, whereas we measured ATG
capable of binding to lymphocytes. Thus, it is possible that
the likelihood of developing aGVHD is reduced by antibodies
within ATG that are capable of binding to cells other than
lymphocytes, for example, to dendritic cells or endothelial
cells, which are known to play an important role in the
pathogenesis of aGVHD [29,30]. But if this is the case, then
why was there a strong association between aGVHD and low
levels of ATG capable of binding to lymphocytes on days þ7
andþ28? Given the association between the decrease in ATG
level from day 0 to day þ28 and aGVHD (Table 4), the cor-
relation between the decreased ATG level and the day þ28
T cell count (Table 5) and the association between high
day þ28 T cell count and aGVHD [31], it is conceivable that
the low levels on day þ7 and day þ28 resulted from high
T cell dose in the graft and/or expansion of alloreactive T cells
between day 0 and daysþ7 andþ28. These Tcells could have
adsorbed ATG, leading to decreased serum concentration.
Thus, the low day þ7 and day þ28 ATG levels may be the
result (and surrogate) of high T cell dose and/or alloreactive
T cell expansion, rather than the cause of insufﬁcient killing/
inhibition of alloreactive T cells leading to aGVHD.
From a practical standpoint, for future studies of ATG
levels as potential biomarkers predicting aGVHD, it may be
important to measure ATG capable of binding to cells other
than lymphocytes or to measure ATG capable of binding to
lymphocytes after day 0.
Similar to Remberger and Sundberg [2] and Remberger
et al. [32], we found no signiﬁcant association between cell
counts in grafts and a drop in ATG level. We also found no
signiﬁcant association between day þ28 WBC or total
lymphocyte count and the relative decrease (or clearance) in
ATG level from day 0 to day þ28. The lack of associationcould be related to the fact that on day þ28, most WBCs are
neutrophils and most lymphocytes are NK cells [28] rather
than T cells that would be expected to adsorb ATG. The half-
life of ATG calculated in our study is comparable to that in
previous studies on clearance of ATG capable of binding to
lymphocytes [12,19].
We found no signiﬁcant association between ATG level at
any of the 3 time points and overall survival, as represented
by death and nonrelapse death. The association of ATG level
with cGVHD is clinically signiﬁcant, however, given that
cGVHD is the most signiﬁcant factor inﬂuencing the quality
of life of transplantation survivors [33]. Thus, a lower inci-
dence of cGVHD in the absence of increased incidence of
relapse is expected to provide meaningful clinical beneﬁt to
transplant recipients.
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